Prognostic value of midtreatment FDG-PET in oropharyngeal cancer.

Published

Journal Article

BACKGROUND: Prognostic metabolic imaging indices are needed for risk stratification for patients with locally advanced oropharyngeal cancer. METHODS: We retrospectively examined pretreatment and midtreatment fluorodeoxyglucose-positron emission tomography (FDG-PET) parameters in patients with locally advanced oropharyngeal cancer who were treated with definitive chemoradiation. RESULTS: A total of 74 patients were evaluated. Pretreatment metabolic tumor volume (MTV) using threshold of 50% standardized uptake value (SUV) maximum (MTV50% ) was associated with progression-free survival (PFS; p = .003; hazard ratio [HR] = 1.57 per 10 cc; 95% confidence interval [CI] = 1.17-2.11) and overall survival (OS; p = .01; HR = 1.36 per 10 cc; 95% CI = 1.07-1.74). Midtreatment MTV using a threshold of SUV 2.0 (MTV2.0 ) was associated with PFS (p < .001; HR = 1.24 per 10 cc; 95% CI = 1.10-1.39) and OS (p = .009; HR = 1.21 per 10 cc; 95% CI = 1.05-1.39). Nodal total lesion glycolysis (TLG) velocity >5% decrease/week was associated with improved PFS (p = .04; HR = 0.37; 95% CI = 0.15-0.95). CONCLUSION: Metabolic response during chemoradiation is associated with survival in locally advanced oropharyngeal cancer and may aid with risk-adapting treatment. © 2016 Wiley Periodicals, Inc. Head Neck 38: First-1478, 2016.

Full Text

Duke Authors

Cited Authors

  • Pollom, EL; Song, J; Durkee, BY; Aggarwal, S; Bui, T; von Eyben, R; Li, R; Brizel, DM; Loo, BW; Le, Q-T; Hara, WY

Published Date

  • October 2016

Published In

Volume / Issue

  • 38 / 10

Start / End Page

  • 1472 - 1478

PubMed ID

  • 27043927

Pubmed Central ID

  • 27043927

Electronic International Standard Serial Number (EISSN)

  • 1097-0347

Digital Object Identifier (DOI)

  • 10.1002/hed.24454

Language

  • eng

Conference Location

  • United States